Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Pancreatic Cancer Specialty Channel

News
Perioperative Modified FOLFIRINOX Shows Promise for Pancreatic Cancer
07/31/2024
According to a phase 2 trial, the use of modified FOLFIRINOX both before and after surgery was feasible and safe, with promising rates of progression-free survival among patients with resectable pancreatic cancer.
According to a phase 2 trial, the use of modified FOLFIRINOX both before and after surgery was feasible and safe, with promising rates of progression-free survival among patients with resectable pancreatic cancer.
According to a phase 2 trial,...
07/31/2024
Oncology
FDA Approval
FDA Approves Irinotecan Liposome for First-Line Metastatic Pancreatic Adenocarcinoma
02/13/2024

Allison Casey 

Allison Casey 
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association...
02/13/2024
Oncology
Ethan Ludmir, MD, MD Anderson Cancer Center
Videos
Adding Metastasis-Directed Therapy for Oligometastatic Pancreas Cancer
01/19/2024

Featuring Ethan Ludmir, MD

Featuring Ethan Ludmir, MD
Ethan Ludmir, MD, discusses results from the phase 2 EXTEND study, evaluating the addition of metastasis-directed therapy for oligometastatic pancreas cancer.
Ethan Ludmir, MD, discusses results from the phase 2 EXTEND study, evaluating the addition of metastasis-directed therapy for oligometastatic pancreas cancer.
Ethan Ludmir, MD, discusses...
01/19/2024
Oncology
News
Nimotuzumab Improved Survival Outcomes for Patients With KRAS Wild-Type Pancreatic Cancer
10/12/2023

Allison Casey 

Allison Casey 
Nimotuzumab plus gemcitabine improved the survival outcomes for patients with locally advanced and metastatic KRAS wild-type pancreatic cancer.
Nimotuzumab plus gemcitabine improved the survival outcomes for patients with locally advanced and metastatic KRAS wild-type pancreatic cancer.
Nimotuzumab plus gemcitabine...
10/12/2023
Oncology
Florence Huguet, MD, PhD, Tenon Hospital at Sorbonne University in Paris
Videos
The Role of Radiation Therapy in Treating Locally Advanced Pancreatic Cancer
08/28/2023

Featuring Florence Huguet, MD, PhD

Featuring Florence Huguet, MD, PhD ...
At the 2023 World Congress on Gastrointestinal Cancers, Florence Huguet, MD, PhD, debated in favor of radiation therapy being used in the treatment of locally advanced pancreatic cancer. 
At the 2023 World Congress on Gastrointestinal Cancers, Florence Huguet, MD, PhD, debated in favor of radiation therapy being used in the treatment of locally advanced pancreatic cancer. 
At the 2023 World Congress on...
08/28/2023
Oncology
Zev Wainberg, MD, University of California - Los Angeles
Videos
NALIRIFOX Regimen As First-Line Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
08/10/2023

Featuring Zev Wainberg, MD

Featuring Zev Wainberg, MD
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presents data from the NAPOLI 3 study, evaluating NALIRIFOX in the first-line setting for patients with metastatic pancreatic ductal adenocarcinoma.
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presents data from the NAPOLI 3 study, evaluating NALIRIFOX in the first-line setting for patients with metastatic pancreatic ductal adenocarcinoma.
At the 2023 World Congress on...
08/10/2023
Oncology
Michael Pishvaian, MD, PhD, Johns Hopkins University
Videos
Intra-Arterial Gemcitabine Showed Promise for Locally Advanced Pancreatic Cancer
08/10/2023

Featuring Michael Pishvaian, MD, PhD

Featuring Michael Pishvaian, MD, PhD ...
At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
At the 2023 World Congress on...
08/10/2023
Oncology
Philip Philip, MD, Wayne State University
Videos
Next-Generation Sequencing for All Patients With Pancreatic Ductal Adenocarcinoma
08/01/2023

Featuring Philip Philip, MD

Featuring Philip Philip, MD
At the 2023 World Congress on Gastrointestinal Cancers, Philip Philip, MD, argued for doing next-generation sequencing for all patients with pancreatic ductal adenocarcinoma.
At the 2023 World Congress on Gastrointestinal Cancers, Philip Philip, MD, argued for doing next-generation sequencing for all patients with pancreatic ductal adenocarcinoma.
At the 2023 World Congress on...
08/01/2023
Oncology
Eileen O'Reilly, MD, Memorial Sloan Kettering Cancer Center
Videos
Current Standards and Emerging Options for Pancreatic Cancer
07/18/2023

Featuring Eileen O'Reilly, MD

Featuring Eileen O'Reilly, MD
At the 2023 World Congress on Gastrointestinal Cancers, Eileen O’Reilly, MD, discusses the existing standards and upcoming options for the treatment of pancreatic cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Eileen O’Reilly, MD, discusses the existing standards and upcoming options for the treatment of pancreatic cancer.
At the 2023 World Congress on...
07/18/2023
Oncology
Conference Coverage
First-Line NALIRIFOX Improves Survival Outcomes for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
06/28/2023
Allison Casey
According to an analysis of the NAPOLI 3 trial, the NALIRIFOX regimen in the first-line setting demonstrated clinically meaningful and statistically significant improvement in overall survival and progression-free survival compared with...
According to an analysis of the NAPOLI 3 trial, the NALIRIFOX regimen in the first-line setting demonstrated clinically meaningful and statistically significant improvement in overall survival and progression-free survival compared with...
According to an analysis of the...
06/28/2023
Oncology
News
Immune Checkpoint Inhibitor Efficacy for MSI/dMMR Advanced Pancreatic Ductal Adenocarcinoma
05/24/2023
Allison Casey
Results from a retrospective study suggest immune checkpoint inhibitors are and effective and well tolerated treatment for patients with MSI/dMMR advanced pancreatic ductal adenocarcinoma.
Results from a retrospective study suggest immune checkpoint inhibitors are and effective and well tolerated treatment for patients with MSI/dMMR advanced pancreatic ductal adenocarcinoma.
Results from a retrospective...
05/24/2023
Oncology

Advertisement

News

News
Perioperative Modified FOLFIRINOX Shows Promise for Pancreatic Cancer
07/31/2024
According to a phase 2 trial, the use of modified FOLFIRINOX both before and after surgery was feasible and safe, with promising rates of progression-free survival among patients with resectable pancreatic cancer.
According to a phase 2 trial, the use of modified FOLFIRINOX both before and after surgery was feasible and safe, with promising rates of progression-free survival among patients with resectable pancreatic cancer.
According to a phase 2 trial,...
07/31/2024
Oncology
FDA Approval
FDA Approves Irinotecan Liposome for First-Line Metastatic Pancreatic Adenocarcinoma
02/13/2024

Allison Casey 

Allison Casey 
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association...
02/13/2024
Oncology
Ethan Ludmir, MD, MD Anderson Cancer Center
Videos
Adding Metastasis-Directed Therapy for Oligometastatic Pancreas Cancer
01/19/2024

Featuring Ethan Ludmir, MD

Featuring Ethan Ludmir, MD
Ethan Ludmir, MD, discusses results from the phase 2 EXTEND study, evaluating the addition of metastasis-directed therapy for oligometastatic pancreas cancer.
Ethan Ludmir, MD, discusses results from the phase 2 EXTEND study, evaluating the addition of metastasis-directed therapy for oligometastatic pancreas cancer.
Ethan Ludmir, MD, discusses...
01/19/2024
Oncology
News
Nimotuzumab Improved Survival Outcomes for Patients With KRAS Wild-Type Pancreatic Cancer
10/12/2023

Allison Casey 

Allison Casey 
Nimotuzumab plus gemcitabine improved the survival outcomes for patients with locally advanced and metastatic KRAS wild-type pancreatic cancer.
Nimotuzumab plus gemcitabine improved the survival outcomes for patients with locally advanced and metastatic KRAS wild-type pancreatic cancer.
Nimotuzumab plus gemcitabine...
10/12/2023
Oncology
Florence Huguet, MD, PhD, Tenon Hospital at Sorbonne University in Paris
Videos
The Role of Radiation Therapy in Treating Locally Advanced Pancreatic Cancer
08/28/2023

Featuring Florence Huguet, MD, PhD

Featuring Florence Huguet, MD, PhD ...
At the 2023 World Congress on Gastrointestinal Cancers, Florence Huguet, MD, PhD, debated in favor of radiation therapy being used in the treatment of locally advanced pancreatic cancer. 
At the 2023 World Congress on Gastrointestinal Cancers, Florence Huguet, MD, PhD, debated in favor of radiation therapy being used in the treatment of locally advanced pancreatic cancer. 
At the 2023 World Congress on...
08/28/2023
Oncology
Zev Wainberg, MD, University of California - Los Angeles
Videos
NALIRIFOX Regimen As First-Line Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
08/10/2023

Featuring Zev Wainberg, MD

Featuring Zev Wainberg, MD
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presents data from the NAPOLI 3 study, evaluating NALIRIFOX in the first-line setting for patients with metastatic pancreatic ductal adenocarcinoma.
At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presents data from the NAPOLI 3 study, evaluating NALIRIFOX in the first-line setting for patients with metastatic pancreatic ductal adenocarcinoma.
At the 2023 World Congress on...
08/10/2023
Oncology
Michael Pishvaian, MD, PhD, Johns Hopkins University
Videos
Intra-Arterial Gemcitabine Showed Promise for Locally Advanced Pancreatic Cancer
08/10/2023

Featuring Michael Pishvaian, MD, PhD

Featuring Michael Pishvaian, MD, PhD ...
At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of a phase 3 study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
At the 2023 World Congress on...
08/10/2023
Oncology
Philip Philip, MD, Wayne State University
Videos
Next-Generation Sequencing for All Patients With Pancreatic Ductal Adenocarcinoma
08/01/2023

Featuring Philip Philip, MD

Featuring Philip Philip, MD
At the 2023 World Congress on Gastrointestinal Cancers, Philip Philip, MD, argued for doing next-generation sequencing for all patients with pancreatic ductal adenocarcinoma.
At the 2023 World Congress on Gastrointestinal Cancers, Philip Philip, MD, argued for doing next-generation sequencing for all patients with pancreatic ductal adenocarcinoma.
At the 2023 World Congress on...
08/01/2023
Oncology
Eileen O'Reilly, MD, Memorial Sloan Kettering Cancer Center
Videos
Current Standards and Emerging Options for Pancreatic Cancer
07/18/2023

Featuring Eileen O'Reilly, MD

Featuring Eileen O'Reilly, MD
At the 2023 World Congress on Gastrointestinal Cancers, Eileen O’Reilly, MD, discusses the existing standards and upcoming options for the treatment of pancreatic cancer.
At the 2023 World Congress on Gastrointestinal Cancers, Eileen O’Reilly, MD, discusses the existing standards and upcoming options for the treatment of pancreatic cancer.
At the 2023 World Congress on...
07/18/2023
Oncology
Conference Coverage
First-Line NALIRIFOX Improves Survival Outcomes for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
06/28/2023
Allison Casey
According to an analysis of the NAPOLI 3 trial, the NALIRIFOX regimen in the first-line setting demonstrated clinically meaningful and statistically significant improvement in overall survival and progression-free survival compared with...
According to an analysis of the NAPOLI 3 trial, the NALIRIFOX regimen in the first-line setting demonstrated clinically meaningful and statistically significant improvement in overall survival and progression-free survival compared with...
According to an analysis of the...
06/28/2023
Oncology

Interactive Features

Quiz
Quiz: Is FOLFIRINOX a Superior Treatment for Patients With Resectable Pancreatic Cancer?
09/08/2021
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the SWOG 1505 trial indicate that FOLFIRINOX was a superior therapy choice compared with gemcitabine plus nab-paclitaxel in patients with resectable pancreatic cancer.
True or false: Results from the...
09/08/2021
Oncology
Quiz
Quiz: Do Molecularly-Matched Therapies Improve OS for Pancreatic Cancer?
08/12/2021
Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.
Molecularly-matched treatments for patients with pancreatic cancer significantly increase overall survival.
Molecularly-matched treatments...
08/12/2021
Oncology
Quiz
Quiz: What is the Median Age of Patients Diagnosed with Pancreatic Cancer?
08/03/2021
True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.
True or False: The median age of patients who are diagnosed with pancreatic cancer is 70 years old.
True or False: The median age of...
08/03/2021
Oncology
Test Your Knowledge
Quiz: Which Combination Benefits Patients with Mesothelin-Expressing Solid Tumors?
08/06/2020
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded manageable safety and encouraging antitumor activity in patients with mesothelin-expressing solid tumors?
Which combination yielded...
08/06/2020
Oncology
Test Your Knowledge
Quiz: Adjuvant Chemoradiation for High-Risk Pancreatic Cancer
09/26/2019
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
True or False: Adding radiation to adjuvant chemotherapy has been shown to encourage a clinically small but meaningful increase in survival.
True or False: Adding radiation...
09/26/2019
Oncology
Test Your Knowledge
Quiz: Durvalumab Combo Therapy for Pancreatic Cancer
08/27/2019
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
Durvalumab therapy plus _______ was well-tolerated but demonstrated poor activity in a study of patients with metastatic pancreatic ductal adenocarcinoma.
Durvalumab therapy plus _______...
08/27/2019
Oncology
Test Your Knowledge
Quiz: Can Hydroxychloroquine Improve OS in Patients With Pancreatic Cancer?
07/09/2019
True or false: In a recent study, adding hydroxychloroquine to chemotherapy improved overall survival in patients with metastatic pancreatic cancer.
True or false: In a recent study, adding hydroxychloroquine to chemotherapy improved overall survival in patients with metastatic pancreatic cancer.
True or false: In a recent...
07/09/2019
Oncology
Test Your Knowledge
Quiz: FOLFIRINOX Outshines Gemcitabine in Pancreatic Cancer
04/17/2019
True or false: Six months of postoperative treatment with the combination of fluorouracil, leucovorin, irinotecan and oxaliplatin (ie, FOLFIRINOX) improved survival rates over conventional gemcitabine therapy in a recent study of patients...
True or false: Six months of postoperative treatment with the combination of fluorouracil, leucovorin, irinotecan and oxaliplatin (ie, FOLFIRINOX) improved survival rates over conventional gemcitabine therapy in a recent study of patients...
True or false: Six months of...
04/17/2019
Oncology
Interactive Case Report
Interactive Case Report: Ectopic ACTH Syndrome From Metastatic Pancreatic Neuroendocrine Tumor
04/04/2018
Ectopic adrenocorticotropic hormone syndrome is a rare disease with a reported incidence of 0.1 cases per million per year.
Ectopic adrenocorticotropic hormone syndrome is a rare disease with a reported incidence of 0.1 cases per million per year.
Ectopic adrenocorticotropic...
04/04/2018
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Perioperative Modified FOLFIRINOX Shows Promise for Pancreatic Cancer
07/31/2024
According to a phase 2 trial, the use of modified FOLFIRINOX both before and after surgery was feasible and safe, with promising rates of progression-free survival among patients with resectable pancreatic cancer.
According to a phase 2 trial, the use of modified FOLFIRINOX both before and after surgery was feasible and safe, with promising rates of progression-free survival among patients with resectable pancreatic cancer.
According to a phase 2 trial,...
07/31/2024
Oncology
FDA Approval
FDA Approves Irinotecan Liposome for First-Line Metastatic Pancreatic Adenocarcinoma
02/13/2024

Allison Casey 

Allison Casey 
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association has granted approval to irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma in the first-line setting.
The US Food and Drug Association...
02/13/2024
Oncology
News
Nimotuzumab Improved Survival Outcomes for Patients With KRAS Wild-Type Pancreatic Cancer
10/12/2023

Allison Casey 

Allison Casey 
Nimotuzumab plus gemcitabine improved the survival outcomes for patients with locally advanced and metastatic KRAS wild-type pancreatic cancer.
Nimotuzumab plus gemcitabine improved the survival outcomes for patients with locally advanced and metastatic KRAS wild-type pancreatic cancer.
Nimotuzumab plus gemcitabine...
10/12/2023
Oncology
News
Immune Checkpoint Inhibitor Efficacy for MSI/dMMR Advanced Pancreatic Ductal Adenocarcinoma
05/24/2023
Allison Casey
Results from a retrospective study suggest immune checkpoint inhibitors are and effective and well tolerated treatment for patients with MSI/dMMR advanced pancreatic ductal adenocarcinoma.
Results from a retrospective study suggest immune checkpoint inhibitors are and effective and well tolerated treatment for patients with MSI/dMMR advanced pancreatic ductal adenocarcinoma.
Results from a retrospective...
05/24/2023
Oncology
News
Sotorasib Monotherapy for Patients With KRAS G12C-Mutated Pancreatic Cancer
03/08/2023

Allison Casey

Allison Casey
According to phase 1/2 trial results, sotorasib monotherapy demonstrated acceptable safety and antitumor activity among previously treated patients with KRAS G12C-mutated pancreatic cancer.
According to phase 1/2 trial results, sotorasib monotherapy demonstrated acceptable safety and antitumor activity among previously treated patients with KRAS G12C-mutated pancreatic cancer.
According to phase 1/2 trial...
03/08/2023
Oncology
News
NALIRIFOX Regimen Improves OS in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
11/15/2022
Allison Casey
The phase 3 NAPOLI 3 trial demonstrated a statistically significant improvement in OS with the NALIRIFOX regimen vs nab-paclitaxel plus gemcitabine for patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
The phase 3 NAPOLI 3 trial demonstrated a statistically significant improvement in OS with the NALIRIFOX regimen vs nab-paclitaxel plus gemcitabine for patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
The phase 3 NAPOLI 3 trial...
11/15/2022
Oncology
News
Neoadjuvant Chemotherapy Associated With Improved OS in Borderline Resectable Pancreatic Cancer
08/09/2022
Allison Casey
Phase 2 trial findings show neoadjuvant modified FOLFIRINOX chemotherapy alone is preferable to modified FOLFIRINOX followed by hypofractionated radiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Phase 2 trial findings show neoadjuvant modified FOLFIRINOX chemotherapy alone is preferable to modified FOLFIRINOX followed by hypofractionated radiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Phase 2 trial findings show...
08/09/2022
Oncology
News
Maintenance Olaparib Yields Clinically Meaningful Benefits for Patients With Metastatic BRCA-Positive Pancreatic Cancer
07/29/2022
Allison Casey
While maintenance olaparib did not significantly improve OS in patients with metastatic pancreatic cancer and a germline BRCA1 or BRCA2 mutation, it did provide clinically meaningful benefits in time off chemotherapy and long-term survival.
While maintenance olaparib did not significantly improve OS in patients with metastatic pancreatic cancer and a germline BRCA1 or BRCA2 mutation, it did provide clinically meaningful benefits in time off chemotherapy and long-term survival.
While maintenance olaparib did...
07/29/2022
Oncology
Conference Insider
First-Line Chemo Beneficial for Elderly Patients With Advanced Pancreatic Cancer
06/30/2021
According to findings presented at the virtual ESMO World Congress on GI Cancer, elderly patients with advanced pancreatic cancer benefit from first-line chemo.
According to findings presented at the virtual ESMO World Congress on GI Cancer, elderly patients with advanced pancreatic cancer benefit from first-line chemo.
According to findings presented...
06/30/2021
Oncology
News
Experts Convene to Debate and Discuss Updates in GI Cancer Care Research
08/10/2020
At the virtual 2020 Great Debates and Updates in GI Malignancies, experts in the oncology space will discuss and debate advancements in therapies for GI cancers.
At the virtual 2020 Great Debates and Updates in GI Malignancies, experts in the oncology space will discuss and debate advancements in therapies for GI cancers.
At the virtual 2020 Great...
08/10/2020
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement